TactiFlex Ablation Catheter, Sensor Enabled
ABBOTT MEDICAL · Decision date Sep 22, 2026
What did the FDA approve?
FDA records an approval decision dated 2026-09-22 for P220013/S034, a 30-day notice supplement (review track 135) filed by Abbott Medical under product code OAE for the TactiFlex Ablation Catheter, Sensor Enabled, a percutaneous cardiac ablation catheter for atrial fibrillation. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier.
The stated scope is approval of a predetermined change control plan, TactiFlex Ablation Catheter, Sensor Enabled Predetermined Change Control Plan Version A, covering a change to the manufacturing location of the deflectable subassembly for the device. This supplement concerns that manufacturing plan and does not represent approval of a new device or system; the source does not describe clinical data, performance testing, or the specific new location, so no conclusion about safety or effectiveness follows from the decision record.
FDA approval order statement
approval for a predetermined change control plan (PCCP) TactiFlex Ablation Catheter, Sensor Enabled Predetermined Change Control Plan Version A that encompasses the change to the manufacturing location of the deflectable subassembly for subject catheter.
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 22, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220013/S034
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- OAE
- Decision code
- APPR
- Decision date
- Sep 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.
- Applicant
- Abbott Medical
- Product code
- OAE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220013 · Original PMA
TactiFlex Ablation Catheter, Sensor Enabled, TactiSys Quartz Equipment, TactiSys Quartz, TactiFlex Radiofrequency C
P220013/S034 received
Application receipt date recorded by FDA.
P220013/S028 · Related supplement
TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDM
P220013/S034 · FDA decision
135 Review Track For 30-Day Notice
Timeline entries are records held by MedtechLedger for P220013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | May 18, 2023 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 4, 2026 | FDA |
Explore the linked device profile
Other records with product code OAE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
STOP Persistent AFP100010/S154 | Medtronic Cryocath, LP | PMA supplement | Sep 25, 2026 | FDA |
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
QDOT MICRO SystemP210027/S018 | Biosense Webster, Inc. | PMA supplement | Sep 10, 2026 | FDA |
QDOT MICRO SystemP210027 | Biosense Webster, Inc. | PMA approval | Nov 23, 2022 | FDA |
| Medtronic Cryocath, LP | PMA approval | Dec 17, 2010 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 5050 Nathan Ln. N., Plymouth, MN, 55442
Sources and methodology
- Original FDA record: P220013/S034
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


